(Mupadolimab)Biosimilar Reference Antibody-GS40450 新品

货号：GS40450

Mupadolimab (also known as CPI‑006) is a humanized IgG1‑kappa monoclonal antibody targeting CD73 (ecto‑5′‑nucleotidase), an enzyme that converts extracellular AMP into adenosine—an immunosuppressive metabolite. A key feature of mupadolimab is its FcγR‑binding‑deficient (Fc‑silent) design, which minimizes effector functions (e.g., ADCC, CDC) and focuses the mechanism on direct immunomodulation. Rather than simply blocking CD73 enzymatic activity, mupadolimab acts as an agonist of CD73‑positive B cells, promoting their activation, maturation, expression of antigen‑presentation markers, and secretion of IgM and IgG. It is being developed as an immune‑activating therapy for advanced cancers, with the goal of enhancing anti‑tumor B‑cell and T‑cell responses.